Jiaqiang (JQ) Cai
Co-Founder & Chief Scientific Officer Medilink Therapeutics
Seminars
Monday 12th October 2026
Expanding ADC Target Applications Through Innovative Linker Payload Chemistry Releasing Payload Without Internalization
12:00 pm
- Utilizing novel linker chemistry to circumvent the need for ADC internalization for payload release
- Applying novel linker payload technology to unlock development against previously inaccessible ADC targets
- Demonstrating novel target accessibility through preclinical efficacy and safety data of anti-VEGF avastin ADC YL242
